4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives $29.88 Average Target Price from Analysts

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) have earned an average rating of “Moderate Buy” from the nine ratings firms that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the company. The average 12-month price target among brokers that have covered the stock in the last year is $29.8750.

Several equities analysts recently weighed in on FDMT shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research report on Monday, April 20th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $21.00 price target (down from $40.00) on shares of 4D Molecular Therapeutics in a research report on Monday, March 30th. Royal Bank Of Canada raised their price target on shares of 4D Molecular Therapeutics from $32.00 to $35.00 and gave the company an “outperform” rating in a research report on Thursday, March 19th. Wall Street Zen cut shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Finally, Chardan Capital reiterated a “buy” rating and issued a $26.00 price objective on shares of 4D Molecular Therapeutics in a research note on Thursday, March 19th.

4D Molecular Therapeutics Stock Performance

Shares of NASDAQ FDMT opened at $8.83 on Wednesday. 4D Molecular Therapeutics has a fifty-two week low of $3.68 and a fifty-two week high of $12.34. The stock has a market cap of $461.63 million, a price-to-earnings ratio of -3.44 and a beta of 2.75. The firm’s 50-day simple moving average is $9.48 and its 200 day simple moving average is $9.19.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($0.04). 4D Molecular Therapeutics had a negative net margin of 182.34% and a negative return on equity of 36.83%. The business had revenue of $3.05 million during the quarter, compared to the consensus estimate of $2.59 million. On average, sell-side analysts predict that 4D Molecular Therapeutics will post -3.8 EPS for the current year.

Institutional Investors Weigh In On 4D Molecular Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Evergreen Quality Fund GP Ltd. purchased a new stake in 4D Molecular Therapeutics in the 4th quarter valued at about $7,136,000. Baker BROS. Advisors LP purchased a new stake in 4D Molecular Therapeutics in the 4th quarter valued at about $3,568,000. Landing Point Financial Group LLC purchased a new stake in 4D Molecular Therapeutics in the 4th quarter valued at about $142,000. AXQ Capital LP increased its stake in 4D Molecular Therapeutics by 138.8% in the 4th quarter. AXQ Capital LP now owns 30,755 shares of the company’s stock valued at $231,000 after buying an additional 17,876 shares during the last quarter. Finally, Impact Partnership Wealth LLC increased its stake in 4D Molecular Therapeutics by 36.5% in the 4th quarter. Impact Partnership Wealth LLC now owns 15,123 shares of the company’s stock valued at $113,000 after buying an additional 4,045 shares during the last quarter. Hedge funds and other institutional investors own 99.27% of the company’s stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.